Drugs Made In America Revises PAGC Merger Terms, Standalone Value Put at $1.71 Billion
Drugs Made In America amended its merger pact with Power Analytics Global, setting a $1.71 billion standalone value for PAGC if the APQC deal stalls.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Drugs Made In America Acquisition has signed an amendment to its existing merger pact with Power Analytics Global. Dated October 13, 2026, the document changes the deal's valuation and closing requirements, according to TradingView, which based its report on filings with the SEC.
If the APQC transaction is not closed by November 1, 2026, or another specified trigger takes place, PAGC would be valued at $1.71 billion on a standalone basis. Payment would be made entirely in shares at the Reference Price, and no earnout is included.
The amendment allows appraised assets to be added later through a further amendment, but the combined value cannot exceed $2.85 billion. After any reversion event, an independent evaluator would issue a fairness opinion.
why it matters
For investors, the key point is that the deal moves toward a standalone scenario settled in shares, which could affect the capital structure of the parties involved. The deal is moderate in size, so the effect on the broader market is likely limited.
tags
instruments
sources
- Drugs Made In America Acquisition Amends PAGC Merger; Standalone Valuation Set at $1.71 Billion — TradingView, 21 October 2026 at 21:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗